Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sipai Health Technology Co's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of Sipai Health Technology Co was 29.19. The lowest was 29.19. And the median was 29.19.
FRA:AX1's Price-to-Net-Cash is not ranked *
in the Medical Distribution industry.
Industry Median: 3.4 * Ranked among companies with meaningful Price-to-Net-Cash only.
Sipai Health Technology Co (FRA:AX1) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Sipai Health Technology Co Net Cash per Share Related Terms
Sipai Health Technology Co Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sipai Health Technology Co Net Cash per Share Chart
FRA:AX1 vs MCK, COR, CAH: Net Cash per Share Comparison
For the Medical Distribution subindustry, Sipai Health Technology Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sipai Health Technology Co Price-to-Net-Cash vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Sipai Health Technology Co's Price-to-Net-Cash falls into.
Sipai Health Technology Co Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Sipai Health Technology Co's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sipai Health Technology Co (FRA:AX1) has a Net Cash per Share of €-0.01 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sipai Health Technology Co and its competitors. According to the industry distribution chart, Sipai Health Technology Co ranks #999999 out of 5 companies in the Medical Distribution industry.
Is Sipai Health Technology Co's Net Cash per Share too high?
Sipai Health Technology Co's current Net Cash per Share is €-0.01. Based on the distribution chart, Sipai Health Technology Co ranks #999999 out of 5 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's Net Cash per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sipai Health Technology Co ranks #999999 out of 5 companies for Net Cash per Share. This places Sipai Health Technology Co in the lower half of its industry. The industry median Net Cash per Share is 3.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Distribution company?
The median Net Cash per Share among Medical Distribution companies is 3.40, based on 5 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sipai Health Technology Co and its competitors. For the Medical Distribution industry, the median Net Cash per Share is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sipai Health Technology Co's current Net Cash per Share is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current Net Cash per Share of €-0.01. The stock's GF Value™ is €0.23, compared to a current price of €0.15 — trading 33% below its estimated fair value. The current Net Cash per Share is €-0.01. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current Net Cash per Share is €-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?
Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued.
The current stock price of €0.15 is trading 33% below its estimated GF Value™ of €0.23.
Key valuation signals for FRA:AX1:
Net Cash per Share: €-0.01
GF Value™: €0.23 vs. price of €0.15 (33% below fair value)
No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score
Get the complete analysis for FRA:AX1
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX1 has been successfully added to your 
